摘要
自1971年7月～1982年12月应用秋水仙硷制剂和CU方案围手术辅助治疗乳腺癌420例。总的10年以上生存率为56％，其中有效组（CR＋PR）与无效组（SD＋PD）分别为71％及48．6％（P＝0．00001）。肿瘤对本前化疗药物越敏感预后越好，其中CR组经病理证实腋淋巴结转移率仅30％，局部欠发率为5％，10年以上生存率达到了85％。作者认为乳腺癌的因手术辅助化疗，尤其是术前有效药物的化疗对改善预后有较好的效果。
From July 1971 to December 1982, 420 operated cases of breast cancer received colchicine plus uraphetine as a perioperative adjuvant chemotherapy. The overall 10-year survival rate was 56%. The same rates in the responded group and the non-responded group were 71% and 48. 6% respectively (P=0. 00001). The more pronounced the tumor responded to chemotherapy, the better the prognosis was. The rate of involvement of the axillary lymph node in the CR group was 30% and the local recurrent rate was 5%. The 10-year survival rate of this series was 85%. The authors suggest that the perioperative chemotherapy of breast cancer as an adjuvant therapy may be helpful to improve the long term outcome of the patient.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
1997年第9期665-668,共4页
Chinese Journal of Clinical Oncology
